Imagen funcional tumoral. Parte 2

García Figueiras R, Padhani AR, Vilanova Busquets JC, Goh V, Villalba Martin C. Imagen funcional tumoral. Parte 1. Radiología Gorospe Sarasúa, 2006, Positron-emission tomography/computed tomography: Artifacts and pitfalls in cancer patients, Radiología, 48, 189, 10.1016/S0033-8338(06)73156-3 Maldonado, 2009, Oncologic PET-CT: The importance of a multidisciplinary team, Radiología, 51, 6, 10.1016/S0033-8338(09)70400-X Torigian, 2007, Functional imaging of cancer with emphasis on molecular techniques, CA Cancer J Clin, 57, 206, 10.3322/canjclin.57.4.206 Poeppel, 2009, PET/CT for the staging and follow-up of patients with malignancies, Eur J Radiol, 70, 382, 10.1016/j.ejrad.2009.03.051 De Geus-Oei, 2008, Predictive and prognostic value of FDG-PET, Cancer Imaging, 8, 70, 10.1102/1470-7330.2008.0010 Freire Macias, 2008, Application clinique des nouveaux traceurs TEP en oncology. La vision d’un médecin nucléaire en Espagne, Médecine Nucléaire, 32, 546, 10.1016/j.mednuc.2008.07.004 Kwock, 2006, Clinical role of proton magnetic resonance spectroscopy in oncology: Brain, breast, and prostate cancer, Lancet Oncol, 7, 859, 10.1016/S1470-2045(06)70905-6 Evelhoch, 2005, Expanding the use of magnetic resonance in the assessment of tumor response to therapy: Workshop report, Cancer Res, 65, 7041, 10.1158/0008-5472.CAN-05-0674 Moller-Hartmann, 2002, Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions, Neuroradiology, 44, 371, 10.1007/s00234-001-0760-0 Majós, 2005, Magnetic resonance spectroscopy for diagnosing brain tumors, Radiología, 47, 1, 10.1016/S0033-8338(05)72790-9 Vilanova, 2009, Peripheral zone prostate cancer in patients with elevated PSA levels and low free-to-total PSA ratio: Detection with MR imaging and MR spectroscopy, Radiology, 253, 135, 10.1148/radiol.2531082049 Zakian, 2005, Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy, Radiology, 234, 804, 10.1148/radiol.2343040363 Stanwell, 2007, In vivo proton MR spectroscopy of the breast, Radiographics, 27, S253, 10.1148/rg.27si075519 Meisamy, 2004, Neoadjuvant chemotherapy of locally advanced breast cancer: Predicting response with in vivo 1H MR spectroscopy. A pilot study at 4.0T, Radiology, 233, 424, 10.1148/radiol.2332031285 Katz-Brull, 2002, Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions, J Natl Cancer Inst, 94, 1197, 10.1093/jnci/94.16.1197 King, 2004, In vivo proton MR spectroscopy of primary and nodal nasopharyngeal carcinoma, AJNR Am J Neuroradiol, 25, 484 King, 2005, Human cervical lymphadenopathy: Evaluation with in vivo 1H-MRS at 1·5T, Clin Radiol, 60, 592, 10.1016/j.crad.2004.11.012 Mahon, 2004, 1H magnetic resonance spectroscopy of invasive cervical cancer: An in vivo study with ex vivo corroboration, NMR Biomed, 17, 1, 10.1002/nbm.830 Schwartz, 2009, Evaluation of lymph nodes with RECIST 1.1, Eur J Cancer, 45, 261, 10.1016/j.ejca.2008.10.028 Van Trappen, 2002, Lymphatic dissemination of tumour cells and the formation of micrometastases, Lancet Oncol, 3, 44, 10.1016/S1470-2045(01)00621-0 Brown, 2003, Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison, Radiology, 227, 371, 10.1148/radiol.2272011747 Whittaker, 2009, Diffusion-weighted MR imaging of female pelvic tumors: A pictorial review, Radiographics, 29, 759, 10.1148/rg.293085130 Holzapfel, 2009, Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes, Eur J Radiol, 72, 381, 10.1016/j.ejrad.2008.09.034 Vandecaveye, 2009, Head and neck squamous cell carcinoma: Value of diffusion-weighted MR imaging for nodal staging, Radiology, 251, 134, 10.1148/radiol.2511080128 Kwee, 2009, ADC measurements of lymph nodes: Inter- and intra-observer reproducibility study and an overview of the literature, Eur J Radiol Misselwitz, 2006, MR contrast agents in lymph node imaging, Eur J Radiol, 58, 375, 10.1016/j.ejrad.2005.12.044 Harisinghani, 2003, Noninvasive detection of clinically occult lymph-node metastases in prostate cancer, N Engl J Med, 348, 2491, 10.1056/NEJMoa022749 Narayanan, 2009, Pearls and pitfalls of MR lymphography in gynecologic malignancy, Radiographics, 29, 1057, 10.1148/rg.294085231 Saksena, 2006, Comparison of lymphotropic nanoparticle-enhanced MRI sequences in patients with various primary cancers, AJR Am J Roentgenol, 187, W582, 10.2214/AJR.05.0873 Thoeny, 2009, Combined ultrasmall superparamagnetic particles of iron oxide–enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients, Eur Urol, 55, 761, 10.1016/j.eururo.2008.12.034 Vapel, 2004, Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response, Oncologist, 9, 4, 10.1634/theoncologist.9-90005-4 Rasheed, 2008, Angiogenesis and hypoxic factors in colorectal cancer, Pathol Res Pract, 204, 501, 10.1016/j.prp.2008.03.005 Rajendran, 2005, Imaging hypoxia and angiogenesis in tumors, Radiol Clin North Am, 43, 169, 10.1016/j.rcl.2004.08.004 Padhani, 2007, Imaging oxygenation of human tumours, Eur Radiol, 17, 861, 10.1007/s00330-006-0431-y Zahra, 2007, Dynamic contrast-enhanced MRI as a predictor of tumour response to radiotherapy, Lancet Oncol, 8, 63, 10.1016/S1470-2045(06)71012-9 Newbold, 2009, An exploratory study into the role of dynamic contrast-enhanced magnetic resonance or perfusion computed tomography for detection of intratumoral hypoxia in head-and-neck cancer, Int J Radiation Oncology Biol Phys, 74, 29, 10.1016/j.ijrobp.2008.07.039 Hoskin, 2007, Hypoxia in prostate cancer: Correlation of BOLD-MRI with pimonidazole immunohistochemistry: Initial observations, Int J Radiat Oncol Biol Phys, 68, 1065, 10.1016/j.ijrobp.2007.01.018 Thorwarth, 2005, Kinetic analysis of dynamic 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer, BMC Cancer, 5, 152, 10.1186/1471-2407-5-152 Komar, 2008, 18F-EF5: A new PET tracer for imaging hypoxia in head and neck cancer, J Nucl Med, 49, 1944, 10.2967/jnumed.108.053785 Miles, 2008, Warburg revisited: Imaging tumour blood flow and metabolism, Cancer Imaging, 8, 81, 10.1102/1470-7330.2008.0011 Goh, 2009, Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study, Eur Radiol, 19, 79, 10.1007/s00330-008-1128-1 Reinsberg, 2007, Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection, AJR Am J Roentgenol, 188, 91, 10.2214/AJR.05.2198 Kauzcor, 2005, Multimodal imaging and computer assisted diagnosis for functional tumour characterization, Cancer Imaging, 5, 46, 10.1102/1470-7330.2005.0013 Eisenhauer, 2009, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Marcus, 2009, Imaging techniques to evaluate the response to treatment in oncology: Current standards and perspectives, Crit Rev Oncol Hematol, 72, 217, 10.1016/j.critrevonc.2008.07.012 Desar, 2009, Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy, Cancer Treat Revs, 35, 309, 10.1016/j.ctrv.2008.12.001 Galbraith, 2003, Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging, J Clin Oncol, 21, 2831, 10.1200/JCO.2003.05.187 Jain, 2005, Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy, Science, 307, 58, 10.1126/science.1104819 Turkbey, 2009, Imaging of tumor angiogenesis: Functional or targeted?, AJR Am J Roetgenol, 193, 304, 10.2214/AJR.09.2869 Gwyther, 2008, How to assess anti-tumour efficacy by imaging techniques, Eur J Cancer, 44, 39, 10.1016/j.ejca.2007.10.010 Knopp, 1994, MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy, Magn Reson Imaging Clin N Am, 2, 633, 10.1016/S1064-9689(21)00131-8 Koh, 2007, Predicting response of colorectal hepatic metastasis: Value of pretreatment apparent diffusion coefficients, AJR Am J Roentgenol, 188, 1001, 10.2214/AJR.06.0601 Dzik-Jurasz, 2002, Diffusion MRI for prediction of response of rectal cancer to chemoradiation, Lancet, 360, 307, 10.1016/S0140-6736(02)09520-X Hamstra, 2008, Functional diffusion map as an early imaging biomarker for high-grade glioma: Correlation with conventional radiologic response and overall survival, J Clin Oncol, 26, 3387, 10.1200/JCO.2007.15.2363 Pickles, 2006, Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer, Magn Reson Imaging, 24, 843, 10.1016/j.mri.2005.11.005 Hamstra, 2007, Diffusion magnetic resonance imaging: A biomarker for treatment response in oncology, J Clin Oncol, 25, 4104, 10.1200/JCO.2007.11.9610 Ng, 2006, Lung cancer perfusion at multi–detector row CT: Reproducibility of whole tumor quantitative measurements, Radiology, 239, 547, 10.1148/radiol.2392050568 Patterson, 2008, Technology insight: Water diffusion MRI--a potential new biomarker of response to cancer therapy, Nat Clin Pract Oncol, 5, 220, 10.1038/ncponc1073 Weber, 1999, Reproducibility of metabolic measurements in malignant tumors using FDG PET, J Nucl Med, 40, 1771 Wahl, 2009, From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors, J Nucl Med, 50, 122S, 10.2967/jnumed.108.057307 Young, 1999, Eur J Cancer, 35, 1773, 10.1016/S0959-8049(99)00229-4 Curran, 2006, Imaging response assessment in oncology, Cancer imaging, 6, S126, 10.1102/1470-7330.2006.9039 Hylton, 2006, Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker, J Clin Oncol, 24, 3293, 10.1200/JCO.2006.06.8080 Jubb, 2006, Predicting benefit from antiangiogenic agents in malignancy, Nature, 6, 626 Abdulkader, 2009, EGFR expression correlates with maximum standardized uptake value of 18F-fluorodeoxyglucose-PET in squamous cell lung carcinoma, Curr Radiopharm, 2, 175, 10.2174/1874471010902030175 O’Connor, 2008, Quantitative imaging biomarkers in the clinical development of targeted therapeutics: Current and future perspectives, Lancet Oncol, 9, 766, 10.1016/S1470-2045(08)70196-7